Journal of Thoracic Oncology. 2011 Jan 4. [Epub ahead of print] [Link]
KaoSubramanian J, Corrales L, Soulieres D, Morgensztern D, Govindan R.
*Division of Oncology, Department of Medicine, Washington University School of Medicine; â€ Department of Medicine, Alvin J Siteman Cancer Center at Washington University School of Medicine, St Louis, Missouri; and â€¡Department of Medicine, Centre Hospitalier de l’UniversitÃ© de MontrÃ©al, Montreal, Canada.
Globally, lung cancer remains the most common cause of cancer-related death. In recent years, it has become clear that development of rational molecular targeted therapies is critical to improve the outcomes of patients with lung cancer. A better understanding of the tumor biology is crucial to achieve this goal. Several new findings in the field of tumor biology were presented at the 46th Annual Meeting of the American Society of Clinical Oncology. Novel genetic mutations were identified in pleural mesothelioma using array-based technologies. Several studies on the development and testing of new molecular diagnostic tests to detect epidermal growth factor receptor tyrosine kinase mutations and EML4-ALK (Echinoderm Microtubule-associated Protein like 4 Anaplastic Lymphoma Receptor Tyrosine Kinase) fusion gene were presented as well.